Insulin detemir is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection for subcutaneous use. MedsAcross supplies Insulin detemir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LEVEMIR is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use LEVEMIR is not recommended for the treatment of diabetic ketoacidosis. LEVEMIR is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis.
Source: US FDA prescribing information
The primary activity of insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Source: US FDA prescribing information
• See Full Prescribing Information for important administration instructions. • Inject subcutaneously into the thigh, upper arm, or abdomen. • Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. • Individualize and titrate the dose of LEVEMIR based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal. • Administer subcutaneously once daily or in divided doses twice daily. • See Full Prescribing Information for recommended starting dose in insulin naïve patients and patients already on insulin therapy.
Source: US FDA prescribing information
LEVEMIR is contraindicated: • During episodes of hypoglycemia • In patients with hypersensitivity to insulin detemir or any of the excipients in LEVEMIR. Reactions have included anaphylaxis. • During episodes of hypoglycemia. • Hypersensitivity to insulin detemir or any of the excipients in LEVEMIR
Source: US FDA prescribing information
• Never Share a LEVEMIR FlexPen, insulin syringe, or needle between patients, even if the needle is changed. • Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. • Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitant drugs, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. • Hypoglycemia due to medication errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection.
Source: US FDA prescribing information
The following adverse reactions are discussed elsewhere: • Hypoglycemia • Hypoglycemia Due to Medication errors • Hypersensitivity Reactions • Hypokalemia Adverse reactions associated with LEVEMIR include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, rash and pruritus.
Source: US FDA prescribing information
Table 6 includes clinically significant drug interactions with LEVEMIR. Table 6: Clinically Significant Drug Interactions with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Insulin detemir, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Levemir 100 IU/mL injectionSubcutaneous | A-S Medication Solutions | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Insulin detemir in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Insulin detemir and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Insulin detemir, including Levemir.
Yes. The US FDA first approved Insulin detemir on 19 October 2005, according to Drugs@FDA.
Yes. Insulin detemir has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Insulin detemir is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Insulin detemir is classified under ATC code A10AE05 (Insulin detemir).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.